Article Text

PDF
Off-label use of inhaled tobramycin in Ontario, Canada
  1. Mina Tadrous1,2,3,
  2. Wayne Khuu2,
  3. J Michael Paterson2,4,5,6,
  4. Muhammad M Mamdani1,2,3,4,7,8,
  5. David N Juurlink2,4,8,9,10,
  6. Tara Gomes1,2,3
  1. 1St. Michael's Hospital, Toronto, Ontario, Canada
  2. 2Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
  3. 3The Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
  4. 4Health Policy, Management, Evaluation, University of Toronto, Toronto, Ontario, Canada
  5. 5Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada
  6. 6Centre for Evaluation of Medicines, St. Joseph's Healthcare, Hamilton, Ontario, Canada
  7. 7Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada
  8. 8Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  9. 9Sunnybrook Research Institute, Toronto, Ontario, Canada
  10. 10Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada
  1. Correspondence to Dr Mina Tadrous, St. Michael's Hospital, 30 Bond St, Toronto, Ontario, Canada M5B 1W8; tadrousm{at}smh.ca

Abstract

Inhaled tobramycin solution is indicated for use in the management of Pseudomonas aeruginosa in patients with cystic fibrosis (CF). Concerns have been raised regarding increasing off-label use of inhaled tobramycin, particularly for the management of COPD. We conducted an 8-year repeated cross-sectional study examining the indication for prescription claims for inhaled tobramycin in Ontario paid for by the Public Drug Benefit Program, which covers all Ontario residents with financial needs or aged 65 and older. Inhaled tobramycin prescription claims increased approximately 3 times greater from 86 prescriptions in the second quarter of 2007 to 261 prescriptions in the first quarter of 2015. Approximately half of all prescriptions (range: 46–65%) per quarter were dispensed to patients with CF. A large proportion of prescriptions (range: 31–36%) were dispensed to individuals who did not have a diagnosis of CF but had a diagnosis of COPD. In 2014, there were 324 unique users of inhaled tobramycin solution in the Ontario Public Drug Program (OPDP). Only half of users (54%; n=163) had a diagnosis of CF. Our study found increasing prescriptions of inhaled tobramycin from 2007 to 2015 in the OPDP with approximately half of these claims being for off-label use, mostly among patients with COPD.

  • Cystic Fibrosis
  • COPD epidemiology
  • Bacterial Infection

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Airwaves
    The Triumvirate